Outcome after percutaneous edge-to-edge mitral repair for functional and degenerative mitral regurgitation: A systematic review and meta-analysis

Heart

Volumn 104, Issue 4, 2018, Pages 306-312

  Chiarito, Mauro ^a   Pagnesi, Matteo ^b   Martino, Enrico Antonio ^b   Pighi, Michele ^c   Scotti, Andrea ^b   Biondi Zoccai, Giuseppe ^d   Latib, Azeem ^b,e   Landoni, Giovanni ^b,f   Mario, Carlo Di ^c   Margonato, Alberto ^b,f   Maisano, Francesco ^g   Feldman, Ted ^h   Alfieri, Ottavio ^b,f   Colombo, Antonio ^b,e,f   Godino, Cosmo ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e EMO GVM CENTRO CUORE COLUMBUS   (Italy)

^f VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

degenerative mitral regurgitation; functional mitral regurgitation; meta analysis; percutaneous edge to edge repair

Indexed keywords

ARTICLE; CARDIOVASCULAR RISK; DEGENERATIVE MITRAL REGURGITATION; DEVICE EMBOLIZATION; FUNCTIONAL MITRAL REGURGITATION; HEART FAILURE; HOSPITAL READMISSION; HUMAN; META ANALYSIS; MITRAL VALVE REGURGITATION; MITRAL VALVE REPAIR; MORTALITY RATE; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME; ANNULOPLASTY; HEART VALVE REPLACEMENT; MITRAL VALVE; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES;

CARDIAC VALVE ANNULOPLASTY; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MITRAL VALVE; MITRAL VALVE INSUFFICIENCY; TREATMENT OUTCOME;

EID: 85026678576     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2017-311412     Document Type: Article

References (35)

1. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the management of valvular Heart disease of the european Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS ). Eur J Cardiothorac Surg 2012;42:S1-44.
2. Nishimura RA, Otto CM, Bonow RO, et al. AHA/ACC Guideline for the management of patients with Valvular Heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. Circulation 2014;2014:e521-643.
3. Goel SS, Bajaj N, Aggarwal B, et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: Comprehensive analysis to determine the potential role of MitraClip for this unmet need. J Am Coll Cardiol 2014;63:185-6.
4. Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011;364:1395-406.
5. Whitlow PL, Feldman T, Pedersen WR, et al. Acute and 12-month results with catheterbased mitral valve leaflet repair: The EVEREST II (Endovascular Valve Edge-to-Edge Repair) High risk study. J Am Coll Cardiol 2012;59:130-9.
6. Enriquez-Sarano M, Schaff HV, Orszulak TA, et al. Valve repair improves the outcome of surgery for mitral regurgitation. A multivariate analysis. Circulation 1995;91:1022-8 http://www. ncbi. nlm. nih. gov/pubmed/7850937.
7. Wu AH, Aaronson KD, Bolling SF, et al. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol 2005;45:381-7.
8. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 2009;339:b2700.
9. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-12 http://www. ncbi. nlm. nih. gov/pubmed/10789670.
10. Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014;14:135.
11. DerSimonian R, Laird N, DerSimonian R. Meta-analysis in clinical trials revisited. Contemp Clin Trials 2015;45:139-45.
12. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
13. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ 2001;323:101-5 http://www. pubmedcentral. nih. gov/articlerender. fcgi? artid= 1120714& tool= pmcentrez& rendertype= abstract.
14. Braun D, Lesevic H, Orban M, et al. Percutaneous edge-to-edge repair of the mitral valve in patients with degenerative versus functional mitral regurgitation. Catheter Cardiovasc Interv 2014;84:137-46.
15. Grasso C, Capodanno D, Scandura S, et al. One- and twelve-month safety and efficacy outcomes of patients undergoing edge-to-edge percutaneous mitral valve repair (from the GRASP registry). Am J Cardiol 2013;111:1482-7.
16. Chan PH, She HL, Alegria-Barrero E, et al. Real-world experience of MitraClip for treatment of severe mitral regurgitation. Circ J 2012;76:2488-93.
17. Maisano F, Franzen O, Baldus S, et al. Percutaneous mitral valve interventions in the real world: Early and 1-year results from the ACCESS -EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. J Am Coll Cardiol 2013;62:1052-61.
18. Nickenig G, Estevez-Loureiro R, Franzen O, et al. Percutaneous mitral valve edge-toedge repair: In-hospital results and 1-year follow-up of 628 patients of the 2011-2012 pilot european Sentinel Registry. J Am Coll Cardiol 2014;64:875-84.
19. Rudolph V, Lubos E, Schluter M, et al. Aetiology of mitral regurgitation differentially affects 2-year adverse outcomes after MitraClip therapy in high-risk patients. Eur J Heart Fail 2013;15:796-807.
20. Feldman T, Mauri L, Kar S, et al. The EVEREST II Randomized Controlled Trial of Percutaneous and Surgical reduction of mitral regurgitation Five-Year results stratified by degenerative or functional etiology. EuroIntervention 2014.
21. Feldman T. The EVEREST II REALISM continued access study. 2015.
22. de Marchena E, Badiye A, Robalino G, et al. Respective prevalence of the different carpentier classes of mitral regurgitation: A stepping stone for future therapeutic research and development. J Card Surg 2011;26:385-92.
23. Hung J, Papakostas L, Tahta SA, et al. Mechanism of recurrent ischemic mitral regurgitation after annuloplasty. Circulation 2004;110.
24. Grayburn PA, Foster E, Sangli C, et al. Relationship between the magnitude of reduction in mitral regurgitation severity and left ventricular and left atrial reverse remodeling after MitraClip therapy. Circulation 2013;128:1667-74.
25. Goldstein D, Moskowitz AJ, Gelijns AC, et al. Two-Year outcomes of Surgical treatment of severe ischemic mitral regurgitation. N Engl J Med 2016;374:344-53.
26. McGee EC, Gillinov AM, Blackstone EH, et al. Recurrent mitral regurgitation after annuloplasty for functional ischemic mitral regurgitation. J Thorac Cardiovasc Surg 2004;128:916-24.
27. Flameng W, Herijgers P, Bogaerts K. Recurrence of mitral valve regurgitation after mitral valve repair in degenerative valve disease. Circulation 2003;107:1609-13.
28. Giannini C, Petronio AS, De Carlo M, et al. Integrated reverse left and right ventricular remodelling after MitraClip implantation in functional mitral regurgitation: An echocardiographic study. Eur Hear J - Cardiovasc Imaging 2013;15.
29. Nagatsu M, Ishihara K, Zile MR, et al. The effects of complete versus incomplete mitral valve repair in experimental mitral regurgitation. J Thorac Cardiovasc Surg 1994;107:416-23 http://www. ncbi. nlm. nih. gov/pubmed/8302060.
30. Lim DS, Reynolds MR, Feldman T, et al. Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after transcatheter mitral valve repair. J Am Coll Cardiol 2014;64:182-92.
31. Nardi P, Pellegrino A, Scafuri A, et al. Survival and durability of mitral valve repair surgery for degenerative mitral valve disease. J Card Surg 2011;26:360-6.
32. Schafer U, Maisano F, Butter C, et al. Impact of Preprocedural left ventricular ejection fraction on 1-Year outcomes after MitraClip implantation (from the ACCESS -EU phase I, a prospective, Multicenter, Nonrandomized Postapproval Study of the MitraClip therapy in Europe). Am J Cardiol 2016;118:873-80.
33. Ohno Y, Attizzani GF, Capodanno D, et al. Impact of chronic kidney disease on outcomes after percutaneous mitral valve repair with the MitraClip system: Insights from the GRASP registry. EuroIntervention 2016;11:e1649-e1657.
34. Gillinov AM, Blackstone EH, Rajeswaran J, et al. Ischemic versus degenerative mitral regurgitation: Does etiology affect survival? Ann Thorac Surg 2005;80:811-9.
35. Detaint D, Sundt TM, Nkomo VT, et al. Surgical correction of mitral regurgitation in the elderly: Outcomes and recent improvements. Circulation 2006;114:265-72.